Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02614547
Other study ID # 547-PPD-202 A
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date December 15, 2015
Est. completion date June 22, 2016

Study information

Verified date January 2022
Source Sage Therapeutics
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a multicenter, randomized, double-blind, parallel-group, placebo-controlled study of the efficacy, safety, and pharmacokinetics of SAGE-547 Injection in adult female participants diagnosed with severe postpartum depression.


Recruitment information / eligibility

Status Completed
Enrollment 21
Est. completion date June 22, 2016
Est. primary completion date June 22, 2016
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 45 Years
Eligibility Key Inclusion Criteria: - Participant either must have ceased lactating at Screening; or if still lactating at Screening, must have already fully and permanently weaned their infant(s) from breastmilk; or if still actively breastfeeding at Screening, must agree to cease giving breastmilk to their infant(s) prior to receiving study drug. - Participant had a major depressive episode that began no earlier than the third trimester and no later than the first 4 weeks following delivery, as diagnosed by Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I). - Participant was less than or equal to (<=) six months postpartum. - Participant must be amenable to intravenous therapy. Key Exclusion Criteria: - Active psychosis. - Attempted suicide associated with index case of postpartum depression. - Medical history of seizures. - Medical history of bipolar disorder. Note: suicidal ideation was not an exclusion. Other protocol-defined inclusion/exclusion criteria may apply.

Study Design


Intervention

Drug:
SAGE-547
Administered as intravenous infusion.
Placebo
Administered as intravenous infusion.

Locations

Country Name City State
United States Sage Investigational Site Atlanta Georgia
United States Sage Investigational Site Chapel Hill North Carolina
United States Sage Investigational Site Philadelphia Pennsylvania
United States Sage Investigational Site Worcester Massachusetts

Sponsors (1)

Lead Sponsor Collaborator
Sage Therapeutics

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change From Baseline at End of Treatment Period (at 60 Hours) in Hamilton Rating Scale for Depression (HAM-D) Total Score The HAM-D total score comprises a sum of the 17 individual item scores. Items scored in a range of 0 to 2 include: insomnia (early, middle, late), somatic symptoms (gastrointestinal and general), genital symptoms, loss of weight, and insight. The following items are scored in a range of 0 to 4: agitation, depressed mood, feelings of guilt, suicide, work and activities, retardation, anxiety (psychic and somatic), and hypochondriasis. The total score can range from 0 to 52, and higher scores indicate a greater degree of depression. A negative change from baseline indicates less depression. A positive change from baseline indicates more depression. Baseline, 60 Hours
Secondary Percentage of Participants With HAM-D Response The HAM-D response was defined as having a 50 percent (%) or greater reduction from baseline in HAM-D total score. The HAM-D total score comprises a sum of the 17 individual item scores. Items scored in a range of 0 to 2 include: insomnia (early, middle, late), somatic symptoms (gastrointestinal and general), genital symptoms, loss of weight, and insight. The following items are scored in a range of 0 to 4: agitation, depressed mood, feelings of guilt, suicide, work and activities, retardation, anxiety (psychic and somatic), and hypochondriasis. The total score can range from 0 to 52, and higher scores indicate a greater degree of depression. A negative change from baseline indicates less depression. A positive change from baseline indicates more depression. 60 Hours, Days 7 and 30
Secondary Percentage of Participants With HAM-D Remission The HAM-D remission was defined as having a HAM-D total score of less than or equal to (<=)7. The HAM-D total score comprises a sum of the 17 individual item scores. Items scored in a range of 0 to 2 include: insomnia (early, middle, late), somatic symptoms (gastrointestinal and general), genital symptoms, loss of weight, and insight. The following items are scored in a range of 0 to 4: agitation, depressed mood, feelings of guilt, suicide, work and activities, retardation, anxiety (psychic and somatic), and hypochondriasis. The total score can range from 0 to 52, and higher scores indicate a greater degree of depression. A negative change from baseline indicates less depression. A positive change from baseline indicates more depression. 60 Hours, Days 7, and 30
Secondary Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score The MADRS is a ten-item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes in participants with mood disorders. It was designed as an adjunct to the HAM-D, to be more sensitive than the Hamilton Scale to the changes brought on by antidepressants and other forms of treatment. Each item yielded a score of 0 to 6. The MADRS total score was calculated as the sum of the 10 individual item scores, which ranged from 0 to 60. Higher MADRS scores indicate more severe depression. A negative change from baseline indicate less severe depression. A positive change from baseline indicates more severe depression. Baseline, 60 Hours, Days 7 and 30
Secondary Percentage of Participants With Clinical Global Impression-Improvement (CGI-I) Response The CGI-I item employs a 7-point Likert scale to measure the overall improvement in the participant's condition post-treatment. The investigator rated the participant's total improvement whether or not it was due entirely to drug treatment. Response choices include: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse. The CGI-I was only rated at post-treatment assessments, and by definition, was evaluated against baseline conditions. CGI-I response was defined as having a CGI-I score of "very much improved" or "much improved". 60 Hours, Days 7 and 30
Secondary Change From Baseline in HAM-D Bech 6 Subscale The HAM-D Bech 6 subscale score was calculated as the sum of the following six items: depressed mood, feelings of guilt, work and activities, retardation, psychic anxiety, and general somatic symptoms. Each item is scored in a range of 0 to 2 or 0 to 4, with higher scores indicating a greater degree of depression. The scores were transformed to a scale of 0 to 100, with a higher score indicating a greater degree of depression. A negative change from baseline indicates less depression. A positive change from baseline indicates more depression. Baseline, 60 Hours, Days 7 and 30
Secondary Change From Baseline to 60 Hours in the HAM-D Individual Item Scores The HAM-D comprises individual ratings of the following symptoms scored in a range of 0 to 2: insomnia (early, middle, late), somatic symptoms (gastrointestinal and general), genital symptoms, loss of weight, and insight. The following symptoms are scored in a range of 0 to 4: agitation, depressed mood, feelings of guilt, suicide, work and activities, retardation, anxiety (psychic and somatic), and hypochondriasis. Higher scores indicate a greater degree of depression. A negative change from baseline indicates less depression. A positive change from baseline indicates more depression. Baseline, 60 Hours
Secondary Change From Baseline in Generalized Anxiety Disorder 7-item Scale (GAD-7) Total Score The GAD-7 is a participant-rated, generalized anxiety symptom severity scale. Scoring for GAD-7 generalized anxiety is calculated by assigning scores of 0 = "not at all sure," 1 = "several days," 2 = "over half the days," and 3 = "nearly every day" to the response categories. The GAD-7 total score for the seven items ranges from 0 to 21, where a score of 0 to 4 = minimal anxiety, 5 to 9 = mild anxiety, 10 to 14 = moderate anxiety, and 15 to 21 = severe anxiety. The GAD-7 total score was calculated as the sum of the seven individual item scores. A negative change from baseline indicates less anxiety. A positive change from baseline indicates more anxiety. Baseline, 60 Hours, Day 7 and 30
Secondary Number of Participants With Treatment-Emergent Adverse Events (TEAEs) An adverse event (AE) was defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it did not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A TEAE was defined as an AE with onset on or after the start of study drug infusion, or any worsening of a pre-existing medical condition/AE with onset on or after the start of study drug infusion. Up to 30 days
See also
  Status Clinical Trial Phase
Completed NCT06057012 - A Study of BRII-296 in Adults With Severe Postpartum Depression (PPD) Phase 2

External Links